- Industry
- 1 min read
Daiichi Sankyo looking to sell OTC drug unit for about $900 million - Nikkei Business
Daiichi Sankyo is focusing on developing cancer treatments to offset a revenue drop following patent expirations of its mainstay blood pressure drug.
TOKYO: Japan's Daiichi Sankyo Co is in talks with several companies to sell its wholly owned over-the-counter (OTC) drug unit, with the final price likely to reach around 100 billion yen ($900 million), Nikkei Business reported on Thursday.
Reuters reported earlier this year that Japan's No. 4 drugmaker had hired JPMorgan to advise on the potential sale of the unit, Daiichi Sankyo Healthcare.
A Daichi Sankyo spokesman declined to comment on the Nikkei Business report.
Daiichi Sankyo is focusing on developing cancer treatments to offset a revenue drop following patent expirations of its mainstay blood pressure drug.
Join the community of 2M+ industry professionals
Subscribe to our newsletter to get latest insights & analysis.
COMMENTS
All Comments
By commenting, you agree to the Prohibited Content Policy
PostBy commenting, you agree to the Prohibited Content Policy
PostFind this Comment Offensive?
Choose your reason below and click on the submit button. This will alert our moderators to take actions